Interstitial lung damage due to cocaine abuse: Pathogenesis, pharmacogenomics and therapy

Current Medicinal Chemistry

Volumn 19, Issue 33, 2012, Pages 5607-5611

  Drent, M ^a   Wijnen, P ^b   Bast, A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biotransformation; Cocaine; Cocaine metabolites; Crack; CYP450; Drug induced toxicity; Interstitial lung diseases; Nitroxide radicals; Oxidative stress; Polymorphisms; Redox cycling

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIOXIDANT; ARISTOLOCHIC ACID; CANNABIS; COCAINE; COMFREY EXTRACT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; EPHEDRA EXTRACT; ILLICIT DRUG; IMMUNOGLOBULIN; INTERFERON; METHADONE; METHOTREXATE; MINERAL OIL; NITROFURANTOIN; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RODENTICIDE; SILICON; TALC; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VITAMIN K GROUP; XENOBIOTIC AGENT;

ARTICLE; CLINICAL FEATURE; COCAINE DEPENDENCE; CYP2C GENE; GENE; HUMAN; INCIDENCE; INFLAMMATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG TOXICITY; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; SOCIAL PROBLEM; SYMPTOMATOLOGY; VKORC1 GENE;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE UPTAKE INHIBITORS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; PHARMACOGENETICS; REACTIVE OXYGEN SPECIES;

EID: 84871299156     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803988901     Document Type: Article

References (52)

1. Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake G W. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am. J. Med., 1981;70:542-568.
2. Travis WD, Hunninghake G, King TE, Jr., Lynch DA, Colby T V, Galvin JR, Brown KK, Chung M P, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Muller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am. J. Respir. Crit. Care Med., 2008;177:1338-1347.
3. Meyer KC. Bronchoalveolar lavage as a diagnostic tool. Semin. Respir. Crit. Care Med., 2007;28:546-560.
4. Drent M, Mansour K, Linssen C. Bronchoalveolar lavage in sarcoidosis. Semin. Respir. Crit. Care Med., 2007;28:486-495.
5. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 2005;353:2229-2242.
6. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration, 2004;71:301-326.
7. Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, Haenen GR, Bekers O. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands. Drug Saf., 2008;31:1125-1134.
8. Foucher P, Biour M, Blayac J P, Godard P, Sgro C, Kuhn M, Vergnon JM, Vervloet D, Pfitzenmeyer P, Ollagnier M, Mayaud C, Camus P. Drugs that may injure the respiratory system. Eur. Respir. J., 1997;10:265-279.
9. Bressler R. Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics, 2006;61:12-18.
10. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br. J. Cancer, 2004;91 Suppl 2:S18-23.
11. Drent M, Singh S, Gorgels A P, Hansell DM, Bekers O, Nicholson AG, van Suylen RJ, du Bois RM. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am. J. Respir. Crit. Care Med., 2003;167:958-961.
12. Restrepo CS, Carrillo JA, Martinez S, Ojeda P, Rivera AL, Hatta A. Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. Radiographics, 2007;27:941-956.
13. Susskind H, Weber DA, Volkow ND, Hitzemann R. Increased lung permeability following long-term use of free-base cocaine (crack). Chest, 1991;100:903-909.
14. Mao JT, Huang M, Wang J, Sharma S, Tashkin DP, Dubinett SM. Cocaine down-regulates IL-2-induced peripheral blood lymphocyte IL-8 and IFN-gamma production. Cell. Immunol., 1996;172:217-223.
15. Dicpinigaitis P V, Jones JG, Frymus MM, Folkert VW. "Crack" cocaineinduced syndrome mimicking sarcoidosis. Am. J. Med. Sci., 1999;317:416-418.
16. Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr. Opin. Pulm. Med., 2001;7:43-61.
17. Gotway MB, Marder SR, Hanks DK, Leung JW, Dawn SK, Gean AD, Reddy GP, Araoz PA, Webb WR. Thoracic complications of illicit drug use: an organ system approach. Radiographics, 2002;22 Spec No: S119-135.
18. Kappus H. Oxidative stress in chemical toxicity. Arch Toxicol, 1987;60:144-149.
19. Wang Y, Gray J P, Mishin V, Heck DE, Laskin DL, Laskin JD. Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic. Biol. Med., 2008;44:1169-1179.
20. Taylor MD, Antonini JM, Roberts JR, Leonard SS, Shi X, Gannett PM, Hubbs AF, Reasor MJ. Intratracheal amiodarone administration to F344 rats directly damages lung airway and parenchymal cells. Toxicol. Appl. Pharmacol., 2003;188:92-103.
21. Bast A, Weseler AR, Haenen GR, den Hartog GJ. Oxidative stress and antioxidants in interstitial lung disease. Curr. Opin. Pulm. Med., 2010;16:516-520.
22. Kovacic P, Cooksy AL. Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med. Hypotheses, 2005;64:357-366.
23. Drummer OH. In Clarke's Analytical Forensic Toxicology. Jickells, S.; Negrusz, A., Eds.; The Pharmaceutical Press: London/Grayslake, 2008; pp. 13-42.
24. Pasanen M, Pellinen P, Stenback F, Juvonen RO, Raunio H, Pelkonen O. The role of CYP enzymes in cocaine-induced liver damage. Arch Toxicol, 1995;69:287-290.
25. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen O, Lang MA, Pasanen M. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol, 1994;270:35-43.
26. Rauckman EJ, Rosen GM, Cavagnaro J. Norcocaine nitroxide. A potential hepatotoxic metabolite of cocaine. Mol Pharmacol, 1982;21:458-463.
27. Kloss M W, Rosen GM, Rauckman EJ. Cocaine-mediated hepatotoxicity. A critical review. Biochem. Pharmacol., 1984;33:169-173.
28. Macedo DS, Vasconcelos SM, Andrade-Neto M, Belchior LD, Honorio Junior JE, Goncalves DO, Fonteles MM, Silva MI, Aguiar LM, Viana GS, de Sousa FC. Cocaine-induced status epilepticus and death generate oxidative stress in prefrontal cortex and striatum of mice. Neurochem. Int., 2010;56:183-187.
29. Portugal-Cohen M, Numa R, Yaka R, Kohen R. Cocaine induces oxidative damage to skin via xanthine oxidase and nitric oxide synthase. J. Dermatol. Sci., 2010;58:105-112.
30. Moritz F, Monteil C, Isabelle M, Bauer F, Renet S, Mulder P, Richard V, Thuillez C. Role of reactive oxygen species in cocaine-induced cardiac dysfunction. Cardiovasc. Res., 2003;59:834-843.
31. Weseler AR, Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep, 2010;12:154-161.
32. Delaney K, Hoffman RS. Pulmonary infarction associated with crack cocaine use in a previously healthy 23-year-old woman. Am. J. Med., 1991;91:92-94.
33. Qi S, den Hartog GJ, Bast A. Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels. Toxicol. Appl. Pharmacol., 2009;237:111-118.
34. Ben-Zaken Cohen S, Pare PD, Man SF, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am. J. Respir. Crit. Care Med., 2007;176:113-120.
35. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology, 2003;43:149-173.
36. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by highsensitivity real-time reverse transcription PCR. Yakugaku Zasshi, 2003;123:369-375.
37. Sarikaya D, Bilgen C, Kamataki T, Topcu Z. Comparative cytochrome P450-1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level. Biopharmaceutics & drug disposition, 2006;27:353-359.
38. Carlson G P. Critical appraisal of the expression of cytochrome P450 enzymes in human lung and evaluation of the possibility that such expression provides evidence of potential styrene tumorigenicity in humans. Toxicology, 2008;254:1-10.
39. Nebert D W, Russell D W. Clinical importance of the cytochromes P450. Lancet, 2002;360:1155-1162.
40. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochemical pharmacology, 2005;70:1096-1103.
41. Wijnen PA, Linssen CF, Haenen GR, Bekers O, Drent M. Variant VKORC1 and CYP2C9 Alleles in Patients with Diffuse Alveolar Hemorrhage Caused by Oral Anticoagulants. Molecular diagnosis & therapy, 2010;14:23-30.
42. Tashkin DP, Khalsa ME, Gorelick D, Chang P, Simmons MS, Coulson AH, Gong H, Jr. Pulmonary status of habitual cocaine smokers. Am. Rev. Respir. Dis., 1992;145:92-100.
43. Waien SA, Hayes D, Jr., Leonardo JM. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N. Engl. J. Med., 2001;345:700-701.
44. Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol, 2007;82:656-660.
45. Wijnen PA, Bekers O, Drent M. Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers. Molecular diagnosis & therapy, 2011;15:177-180.
46. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood, 2007;109:2419-2423.
47. Sconce EA, Avery PJ, Wynne HA, Kamali F. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost, 2008;6:1226-1228.
48. Shuster L, Casey E, Welankiwar SS. Metabolism of cocaine and norcocaine to N-hydroxynorcocaine. Biochem. Pharmacol., 1983;32:3045-3051.
49. Zaragoza A, Diez-Fernandez C, Alvarez AM, Andres D, Cascales M. Mitochondrial involvement in cocaine-treated rat hepatocytes: effect of N-acetylcysteine and deferoxamine. Br. J. Pharmacol., 2001;132:1063-1070.
50. Boots AW, Drent M, de Boer VC, Bast A, Haenen GR. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr., 2011;30:506-512.
51. Vitcheva V, Simeonova R, Krasteva I, Yotova M, Nikolov S, Mitcheva M. Hepatoprotective effects of saponarin, isolated from Gypsophila trichotoma Wend. on cocaine-induced oxidative stress in rats. Redox Rep, 2011;16:56-61.
52. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet, 2004;363:731-733.